Diabetes Dialogue: Selection of DDP IV. and SGLT2 Blockers and GLP-1 Analogues: New Controversies

Thursday, December 11, 2014


This conference has already taken place.


The Fawcett Center - Columbus, OH
1 Day Conference December 11th, 2014
1.50 AMA PRA Category 1 Credit Hours

Description

This Dialogue, certified for 1.5 AMA PRA Category 1 credit(s)TM, is a live activity which will incorporate a 60 minute PowerPoint presentation followed by a 30 minutes question and answer session moderated by Dr. Kwame Osei.  This interactive  format will help the learners address professional gaps, allowing healthcare professionals in the community time to get questions pertinent to their clinical practice answered.  The presentations will be given to the attendees and will be available on the website after the event.
Register

For pricing information, see pricing tab below.

Dates and Times

Start: 12/11/2014 12:00 AM
End: 12/11/2014 12:00 AM

Objectives


1. Identify new pathophysiology of type 2 Diabetes
2. Describe the role of GLP-1 Analogues, DDP IV Inhibitors and SGLT2 Receptor Inhibitors in managing Type 2 Diabetes
3. Explain effective strategies in selecting new anti-diabetic medications
4. Assess controversies surrounding the use of GLP-1 Analogues, DDP IV Inhibitors and SGLT2 Receptor Inhibitors

Pricing

Tier Price
All $10.00

Speakers

  • Dr. Kathleen Dungan, MD
    • Diabetes Dialogue: Selection of DDP IV. and SGLT2 Blockers and GLP-1 Analogues: New Controversies

Location

The Fawcett Center
2400 Olentangy River Road
Columbus, OH 43201

Accreditation Statement

The Ohio State University is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

AMA Credit Designation Statement

The Ohio State University designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credit(s) . Physicians should only claim credit commensurate with the extent of their participation in the activity.